ResMed Inc. (RMD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
$252.83 +1.06% NYSE • Public Delayed / 60s Snapshot
ResMed Inc. (RMD) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (59% profit margin, 23% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
ROARABLE B • BUY
Cap $35.56B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw C+ · Rk A-
Each axis scored 0–20
12M PRICE TARGET CONE+7.2% Base Target
WHALE OPTIONS TUG-OF-WAR:56% Call Buyers ($3.6M)
44% PutsMax Pain: $248.00
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)
How RMD Turns Every Dollar of Sales Into Real Bottom-Line Profit
Free Cash Flow:$1.66B (32.3% FCF Margin)
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $4.22B
FY24
Rev $4.69B
FY25
Rev $5.15B
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $5.15B | 59.4% | 32.7% | $1.40B | $1.66B | 22.6% |
| FY 2024 | $4.69B | 56.7% | 28.2% | $1.02B | $1.30B | 18.7% |
| FY 2023 | $4.22B | 44% | 26.8% | $898.0M | $503.3M | 7.6% |
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring RMD)
- ✓Live walkthrough of RMD's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
RMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.54%🛡️ HOLDING TREND SUPPORT
2026-10-30O $246.6H $248.1L $228.3C $229.9VOL 3.45M
RES: $257.3SUP: $226.3SMA50: $231.8SMA200: $224.9
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
19.1%/yr Implied 5Y Growth
vs. +9.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RMD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
LLY → RMD Analyst Hypothesis
FDA approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity introduces the first pharmacologic disease-modifying competitor to ResMed CPAP devices.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
RMD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is ResMed Inc. (RMD)?
In FY 2025 (10-K), RMD converted $5.1B of revenue into a 59.4% gross margin, 32.7% operating margin, and $1.7B in free cash flow (32.3% FCF margin).